May is Ocular Melanoma Awareness Month
Although rare, ocular (uveal) melanoma is the most common primary cancer of the eye in adults with an estimated 2,000 – 3,000 new cases in the United States each year. This type
read more
Dr. Abbey Featured in Retina Times
Texas Retina Associates’ Ashkan Abbey, MD, was featured in the “5 Questions” segment of the latest issue of Retina Today. In the article, he discusses his passion for retina research, what led
read more
What You Should Bring to Your Appointment
Our team at Texas Retina Associates works hard to provide you with personalized, comprehensive care, including an accurate diagnosis and access to the latest treatment options for your condition. To help us,
read more
April is Sports Eye Safety Month
According to the American Academy of Ophthalmology, an estimated 100,000 people are hurt each year by sports-related eye injuries, and about 13,500 of these injuries result in permanent vision loss. Sports eye
read more
Happy Doctors’ Day!
Today we celebrate and thank all 16 of our physicians at Texas Retina Associates as well as all of the physicians who serve our patients and communities. “The good physician treats the
read more
Texas Retina Associates Led the Way at the 2023 VisionWalk to Benefit the Foundation Fighting Blindness
This past Saturday, Texas Retina Associates sponsored and participated in the 2023 Dallas-Fort Worth VisionWalk to benefit the Foundation Fighting Blindness and was recognized as the “Largest Team.” Our “Walk Stars” came
read more
Know the Early Warning Signs of a Retinal Detachment
The retina is the layer of nerve cells lining the back wall inside the eye. It senses light and sends signals to the brain so you can see. The vitreous is the
read more
Dr. Kothari Spoke at EnVision Summit
Last month, Texas Retina Associates’ Nikisha Kothari, MD, presented on the medical and surgical management of macular holes at the EnVision Summit Ophthalmology 2023. A macular hole is a small gap that
read more Four New Clinical Trials Available at Texas Retina Associates
Our physicians remain committed to participating in ongoing retina research and providing our patients access to promising new treatment options through clinical trials. We recently opened four new clinical trials: Diabetic Macular
read more
FDA Approves First Treatment for Geographic Atrophy
On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retina
read more